Published On: Wed, Oct 19th, 2016

Latest Analyst Reports On Kindred Biosciences, Inc.


Recently stock market analysts have updated their consensus ratings on shares of Kindred Biosciences, Inc. (KIN).

Most recent broker ratings

05/17/2016 – Kindred Biosciences, Inc. had its “market perform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 7 price target on the stock.

08/13/2015 – Kindred Biosciences, Inc. had its “hold” rating reiterated by analysts at Roth Capital.

12/04/2014 – Kindred Biosciences, Inc. was downgraded to “market perform” by analysts at Kindred Biosciences. They now have a USD 6 price target on the stock.

12/04/2014 – Kindred Biosciences, Inc. was downgraded to “market perform” by analysts at Leerink Swann. They now have a USD 6 price target on the stock.

11/18/2014 – Kindred Biosciences, Inc. was upgraded to “outperform” by analysts at Zacks. They now have a USD 11.3 price target on the stock.

05/23/2014 – Craig-Hallum began new coverage on Kindred Biosciences, Inc. giving the company a “buy” rating.

01/06/2014 – Guggenheim began new coverage on Kindred Biosciences, Inc. giving the company a “buy” rating.

Kindred Biosciences, Inc. has a 50 day moving average of 4.90 and a 200 day moving average of 4.06. The stock’s market capitalization is 103.43M, it has a 52-week low of 2.90 and a 52-week high of 5.95.

The share price of the company (KIN) was up +0.97%, with a high of 5.35 during the day and the volume of Kindred Biosciences, Inc. shares traded was 54893.

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.